Raymond James Thinks Knight Therapeutics’ Stock is Going to Recover
Today, an analyst has provided a rating update for the Healthcare company, Knight Therapeutics (GUD). Raymond James’ analyst David Novak reiterates their Buy rating on the shares, with a C$10.25 price target.
According to TipRanks.com, Novak is ranked #1922 out of 5259 analysts.
Knight Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of C$9.42, representing a 27.5% upside. In a report released today, GMP FirstEnergy also reiterated a Buy rating on the stock with a C$10 price target.
Based on Knight Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of C$12.93 million. In comparison, last year the company had a net profit of C$7.15 million.
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite.
The company’s shares closed on Friday at C$7.39, close to its 52-week low of C$7.36.